Literature DB >> 11262084

Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

S J Gregson1, P W Howard, J A Hartley, N A Brooks, L J Adams, T C Jenkins, L R Kelland, D E Thurston.   

Abstract

A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits tethered through their C8 positions via an inert propanedioxy linker. This symmetric molecule is a highly efficient minor groove interstrand DNA cross-linking agent (XL(50) = 0.045 microM) that is 440-fold more potent than melphalan. Thermal denaturation studies show that, after 18 h incubation with calf thymus DNA at a 5:1 DNA/ligand ratio, it increases the T(m) value by 33.6 degrees C, the highest value so far recorded in this assay. The analogous dimer 4 (DSB-120) that lacks substitution/unsaturation at the C2 position elevates melting by only 15.1 degrees C under the same conditions, illustrating the effect of introducing C2-exo-unsaturation which serves to flatten the C-rings and achieve a superior isohelical fit within the DNA minor groove. This behavior is supported by molecular modeling studies which indicate that (i) the PBD units are covalently bonded to guanines on opposite strands to form a cross-link, (ii) 5 has a greater binding energy compared to 4, and (iii) 4 and 5 have equivalent binding sites that span six base pairs. Dimer 5 is significantly more cytotoxic than 4 in a number of human ovarian cancer cell lines (e.g., IC(50) values of 0.0225 nM vs 7.2 nM, respectively, in A2780 cells). Furthermore, it retains full potency in the cisplatin-resistant cell line A2780cisR (0.024 nM), whereas 4 loses activity (0.21 microM) with a resistance factor of 29.2. This may be due to a lower level of inactivation of 5 by intracellular thiol-containing molecules. A dilactam analogue (21) of 5 that lacks the electrophilic N10-C11/N10'-C11' imine moieties has also been synthesized and evaluated. Although unable to interact covalently with DNA, 21 still stabilizes the helix (Delta T(m) = 0.78 degrees C) and has significant cytotoxicity in some cell lines (i.e., IC(50) = 0.57 microM in CH1 cells), presumably exerting its effect through noncovalent interaction with DNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262084     DOI: 10.1021/jm001064n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair.

Authors:  Blanka Sengerová; Anderson T Wang; Peter J McHugh
Journal:  Cell Cycle       Date:  2011-12-01       Impact factor: 4.534

Review 2.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

3.  Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.

Authors:  Arnaud C Tiberghien; Jean-Noel Levy; Luke A Masterson; Neki V Patel; Lauren R Adams; Simon Corbett; David G Williams; John A Hartley; Philip W Howard
Journal:  ACS Med Chem Lett       Date:  2016-05-24       Impact factor: 4.345

Review 4.  Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines.

Authors:  Barbara Gerratana
Journal:  Med Res Rev       Date:  2010-06-13       Impact factor: 12.944

5.  Sensing and Processing of DNA Interstrand Crosslinks by the Mismatch Repair Pathway.

Authors:  Niyo Kato; Yoshitaka Kawasoe; Hannah Williams; Elena Coates; Upasana Roy; Yuqian Shi; Lorena S Beese; Orlando D Schärer; Hong Yan; Max E Gottesman; Tatsuro S Takahashi; Jean Gautier
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

6.  Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.

Authors:  Maciej Kaliszczak; Dyeison Antonow; Katan I Patel; Philip Howard; Duncan I Jodrell; David E Thurston; Sylvie M Guichard
Journal:  AAPS J       Date:  2010-08-12       Impact factor: 4.009

7.  Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.

Authors:  Maureen C Ryan; Maria Corinna Palanca-Wessels; Brian Schimpf; Kristine A Gordon; Heather Kostner; Brad Meyer; Changpu Yu; Heather A Van Epps; Dennis Benjamin
Journal:  Blood       Date:  2017-09-13       Impact factor: 22.113

Review 8.  Dimeric approaches to anti-cancer chemotherapeutics.

Authors:  M K Hadden; B S J Blagg
Journal:  Anticancer Agents Med Chem       Date:  2008-10       Impact factor: 2.505

9.  Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.

Authors:  Gary P Wilkinson; James P Taylor; Steve Shnyder; Patricia Cooper; Phil W Howard; David E Thurston; Terence C Jenkins; Paul M Loadman
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

10.  Biosynthesis, Mechanism of Action, and Inhibition of the Enterotoxin Tilimycin Produced by the Opportunistic Pathogen Klebsiella oxytoca.

Authors:  Evan M Alexander; Dale F Kreitler; Valeria Guidolin; Alexander K Hurben; Eric Drake; Peter W Villalta; Silvia Balbo; Andrew M Gulick; Courtney C Aldrich
Journal:  ACS Infect Dis       Date:  2020-06-24       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.